What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Not seeing results on GLP-1 meds like semaglutide? Learn why that might be, and how lifestyle changes and medical support could help you stay on track.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic®, Rybelsus®) and chronic weight management (Wegovy®). It has been shown to help support appetite regulation and improve markers of metabolic health in eligible individuals. However, not everyone experiences immediate or consistent results. If you’re wondering why semaglutide is not working, there are several reasons this may be happening, and actionable steps to help get back on track.
Note: Eden partners with licensed healthcare providers who evaluate patients individually. GLP-1 medications may be prescribed based on medical judgment and are not dispensed directly by Eden.
Semaglutide mimics the GLP-1 hormone, which plays a role in glucose regulation and appetite signaling. FDA-approved versions include:
Licensed healthcare providers, at their discretion, may determine that semaglutide is appropriate for uses beyond its FDA-approved indications. Any such decision requires a personalized discussion between the patient and provider about potential risks, benefits, and alternatives. Eden connects patients with independent, licensed medical professionals who assess eligibility for treatment options.
While semaglutide is approved for specific medical uses, many patients report that, when combined with diet and physical activity, it may:
Disclaimer: Any descriptions of potential benefits are for informational purposes only and are not intended to suggest FDA approval. These statements have not been evaluated by the FDA, and individual results will vary based on health status and provider guidance.
Even when used correctly, it’s common to experience plateaus. This doesn’t mean semaglutide isn’t working, it may just be time to make adjustments.
If you’re concerned that semaglutide is not working, you’re not alone. Many individuals experience slow starts, temporary stalls, or fluctuating progress. The key is to stay consistent, communicate with your licensed medical care team, and make small changes that align with your health goals.
Eden helps connect individuals with licensed healthcare providers who can assess your needs and determine whether GLP-1 therapy is appropriate. If you're already prescribed semaglutide and have hit a plateau, a few strategic tweaks could make all the difference.
This blog is for informational purposes only and does not constitute medical advice. Semaglutide and other GLP-1 medications must be prescribed by a licensed medical provider following a medical evaluation. Eden does not dispense medications but facilitates care with third-party providers and pharmacies. Use of semaglutide for purposes beyond its FDA-approved indications should only occur under the guidance of a licensed healthcare provider, with appropriate clinical oversight and informed consent.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Chang, R. S., Hu, J., & Yeh, H. (2022). Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss. Journal of General Internal Medicine, 37(7), 1824–1826. https://doi.org/10.1007/s11606-021-07215-4
Hall, K. D. (2024). Physiology of the weight‐loss plateau in response to diet restriction, GLP‐1 receptor agonism, and bariatric surgery. Obesity, 32(6), 1163–1168. https://doi.org/10.1002/oby.24027
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024a). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024b). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024c). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Pa-C, C. F. (2025, April 7). How semaglutide affects sleep: Exploring its role in sleep Disorder management. Bmi Doctors. https://bmidoctors.com/how-semaglutide-affects-sleep-exploring-its-role-in-sleep-disorder-management/
Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525
Sato, G., Uchino, H., & Hirose, T. (2024). Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study. Diabetes Therapy, 15(9), 2119–2130. https://doi.org/10.1007/s13300-024-01631-5
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023). Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. Journal of Clinical Medicine, 12(18), 5915. https://doi.org/10.3390/jcm12185915